You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

~ Buy the TAVALISSE (fostamatinib disodium) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR TAVALISSE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for TAVALISSE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02612558 ↗	A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)	Completed	Rigel Pharmaceuticals	Phase 2	2016-07-01	The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
NCT04543279 ↗	Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia	Recruiting	Rigel Pharmaceuticals	Phase 2	2021-05-03	Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet <50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor, ruxolitinib. Additionally, fostamatinib monotherapy may also improve myelofibrosis related symptoms and splenomegaly.
NCT04543279 ↗	Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia	Recruiting	Washington University School of Medicine	Phase 2	2021-05-03	Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet <50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor, ruxolitinib. Additionally, fostamatinib monotherapy may also improve myelofibrosis related symptoms and splenomegaly.
NCT05040698 ↗	Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa	Not yet recruiting	Rigel Pharmaceuticals	Phase 2	2021-10-01	A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.
NCT05040698 ↗	Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa	Not yet recruiting	Holdsworth House Medical Practice	Phase 2	2021-10-01	A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for TAVALISSE

Condition Name

Chart
Table

Condition Name for TAVALISSE
Intervention	Trials
Hidradenitis Suppurativa	1
Myelofibrosis	1
Warm Antibody Autoimmune Hemolytic Anemia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for TAVALISSE
Intervention	Trials
Primary Myelofibrosis	1
Hemolysis	1
Anemia, Hemolytic, Autoimmune	1
Inflammation	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for TAVALISSE

Trials by Country

Map
Table

Trials by Country for TAVALISSE
Location	Trials
United States	20
Canada	3
Australia	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for TAVALISSE
Location	Trials
Missouri	1
Wisconsin	1
West Virginia	1
Washington	1
Utah	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for TAVALISSE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for TAVALISSE
Clinical Trial Phase	Trials
Phase 2	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for TAVALISSE
Clinical Trial Phase	Trials
Recruiting	1
Completed	1
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TAVALISSE

Sponsor Name

Chart
Table

Sponsor Name for TAVALISSE
Sponsor	Trials
Rigel Pharmaceuticals	3
Washington University School of Medicine	1
Holdsworth House Medical Practice	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for TAVALISSE
Sponsor	Trials
Industry	3
Other	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.